FDA: Cemiplimab Given Breakthrough Designation for Advanced Squamous Cell Carcinoma
Treatment with cemiplimab led to an overall response rate (ORR) of 46.2% and a disease control rate of 69.2%
Skin Cancer
Preventing Melanoma With Nicotinamide: Yes or No?
Nicotinamide, a form of vitamin B3 (niacin), is a “promising and well-tolerated” chemopreventive agent for patients at high risk for developing skin cancer, according to the results of a recent review of the agent
Alcohol Intake May Increase Risk of Nonmelanoma Skin Cancer
Alcohol could serve as an important public health target to reduce the global health burden of NMSC.
Need for Nodal Biopsy in Melanoma Factored by Age
Although national guidelines for lymph node biopsies focus on pathology, researchers say patient age is an important factor to take into consideration.
Nivolumab Bests Ipilimumab for Resected Melanoma Recurrence Prevention
Ipilimumab also had a significantly worse adverse event profile with adverse events occurring among 46% of patients.
Adjuvant Nivolumab Linked to Longer Recurrence-Free Survival in Melanoma
Adjuvant therapy with nivolumab is associated with longer recurrence-free survival than therapy with ipilimumab among patients undergoing resection of stage IIIB, IIIC, or IV melanoma.
Resected Melanoma Benefits from Dabrafenib, Trametinib
Adjuvant dabrafenib plus trametinib is associated with a higher rate of relapse-free survival for patients with resected stage III melanoma with BRAF V600E or V600K mutations.
Majority of Melanomas Arise From New Lesions, Not Existing Moles
The majority of melanomas arise from new lesions rather than existing moles.
HAART Lowers Risk of Secondary Cancers After Kaposi Sarcoma
There has been a significant decline in the risk of secondary cancers after Kaposi sarcoma in the era of highly-active antiretroviral therapy.
Patients with Nonmelanoma Skin Cancers Have Higher Levels of Arsenic
Some arsenic species levels are higher in patients with nonmelanoma skin cancer.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...